

Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism

Petrlova, Jitka; Hansen, Finja C.; van der Plas, Mariena J. A.; Huber, Roland G.; Mörgelin, Matthias; Malmsten, Martin; Bond, Peter J.; Schmidtchen, Artur

2017

Petrlova, J., Hansen, F. C., van der Plas, M. J. A., Huber, R. G., Mörgelin, M., Malmsten, M., et al. (2017). Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, 114(21), E4213-E4222.

<https://hdl.handle.net/10356/83618>

<https://doi.org/10.1073/pnas.1619609114>

© 2017 The Author(s) (Published by National Academy of Sciences). This is the author created version of a work that has been peer reviewed and accepted for publication by *Proceedings of the National Academy of Sciences of the United States of America*, The Author(s) (Published by National Academy of Sciences). It incorporates referee's comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [<http://dx.doi.org/10.1073/pnas.1619609114>].

1 Classification: BIOLOGICAL SCIENCES; Immunology and Inflammation.

2

3 **Aggregation of thrombin-derived C-terminal fragments - a novel host defense**

4 **mechanism**

5

6 Jitka Petrlova^{a,1}, Finja C. Hansen^a, Mariena J.A. van der Plas^a, Roland G. Huber^b,

7 Matthias Mörgelin^c, Martin Malmsten^{d,e}, Peter J. Bond^{b,f}, and Artur Schmidtchen^{a,g,h}

8

9 ^aDivision of Dermatology and Venereology, Department of Clinical Sciences, Lund

10 University, Sweden, ^bBioinformatics Institute (A*STAR), Singapore, ^cDivision of

11 Infection Medicine, Department of Clinical Sciences, Lund University, Sweden,

12 ^dDepartment of Pharmacy, Uppsala University, Sweden, ^eDepartment of Pharmacy,

13 University of Copenhagen, Copenhagen, Denmark, ^fDepartment of Biological

14 Sciences, National University of Singapore, Singapore, ^gDermatology, LKC Medicine,

15 Nanyang Technological University, Singapore, ^hDermatology, Skane University

16 Hospital, Sweden

17

18 ¹Corresponding author: Jitka Petrlova, Division of Dermatology and Venereology,

19 Department of Clinical Sciences, Lund University, Sweden; +46 462223315;

20 jitka.petrlova@med.lu.se

21

22

23

24

25

26 **Abstract**

27

28 Effective control of endotoxins and bacteria is crucial for normal wound healing.

29 During injury, the key enzyme thrombin is formed, leading to generation of fibrin.

30 Here we show that human neutrophil elastase (HNE) cleaves thrombin, generating 11-

31 kDa thrombin-derived C-terminal peptides (TCP), which bind to and form amorphous

32 amyloid-like aggregates with both bacterial lipopolysaccharide (LPS) and Gram-

33 negative bacteria. *In silico* molecular modeling employing atomic-resolution and

34 coarse-grained simulations corroborates our experimental observations, altogether

35 indicating increased aggregation through LPS-mediated intermolecular contacts

36 between clusters of TCP molecules. Upon bacterial aggregation, recombinantly

37 produced TCP induces permeabilization of *Escherichia coli* and phagocytic uptake.

38 TCPs of about 11 kDa are present in acute wound fluids as well as in fibrin sloughs

39 from patients with infected wounds. We noted aggregation and colocalization of LPS

40 with TCPs in such fibrin material, which indicates the presence of LPS-TCP

41 aggregates under physiological conditions. Apart from identifying a novel function of

42 proteolysed thrombin and its fragments, our findings provide an interesting

43 link between the coagulation system, innate immunity, LPS-scavenging and protein

44 aggregation/amyloid formation.

45

46

47

48

49

50

51 **Significance**

52

53 The work summarized in this paper is based on the simple but unexpected observation
54 that addition of LPS or bacteria to human wound fluids leads to precipitation of
55 protein aggregates, a phenomenon not observed in plasma. Using a broad mix of
56 technologies, from biophysical, biochemical and microbiological methods,
57 fluorescence and electron microscopy, and in silico modeling, to studies on wound
58 materials, we here demonstrate a previously undisclosed role of C-terminal thrombin
59 fragments of about 11 kDa, involving LPS- and bacteria-induced aggregation and
60 scavenging, facilitating clearance and microbial killing. Our findings provide a novel
61 link between the major coagulation factor thrombin, innate immunity, and amyloid
62 formation.

63

64

65

66

67

68

69

70

71

72

73 \body

74 **Introduction**

75 Skin wounds pose a potential threat for invasive infection and sepsis. It is therefore
76 not surprising that multiple host defense systems have developed over the course of
77 evolution that involve initial hemostasis, fibrin formation, and the subsequent action
78 of multiple proteins and peptides of our innate immune system (1-3). In humans, such
79 host defense systems include neutrophil-derived α -defensins and the cathelicidin LL-
80 37 (3, 4) but also proteolytic products of plasma proteins, such as heparin cofactor II
81 (5), antithrombin III (6), and thrombin (7-10). Lipopolysaccharide sensing by Toll-
82 like receptor 4 (TLR4) is crucial in early responses to infection. However, an
83 excessive LPS response gives rise to dysfunctionality, causing localized inflammation
84 such as that found in infected wounds, but also severe systemic responses such as
85 those seen in sepsis (11). Therefore, clearance and control of endotoxins is critical to
86 maintaining a robust antibacterial response while maintaining control of inflammatory
87 responses. Thrombin-derived C-terminal peptides of roughly 2 kDa (such as
88 FYTHVFRLLKKWIKVIDQFGE and HVFRLLKKWIKVIDQFGE (12-14)), which
89 are present in wounds, frequently form helices upon LPS-binding and exert anti-
90 endotoxic functions *in vitro* and *in vivo* (10, 12). From a therapeutic standpoint, a
91 prototypic thrombin-derived peptide, GKY25
92 (GKYGFYTHVFRLLKKWIKVIDQFGE) has been shown to protect against *P.*
93 *aeruginosa* sepsis, mainly via reduction of both systemic cytokine responses and
94 excessive coagulation (12, 15). Functional and structural studies have thus far focused
95 on this and related low-molecular weight peptides (10, 12); the major 11-kDa TCP-
96 form present in wound fluids (10) remains uncharacterized. During the course of our
97 work, we noted that the 11-kDa TCP was notoriously prone to aggregation, which
98 suggests that this structure may present some unique characteristics that differentiate

99 it from smaller TCPs. This finding prompted us to further investigate biological roles
100 of TCPs.

101

102 **Results**

103 **Purification and activity of rTCP.** First, we generated a recombinant 96-amino acid
104 TCP fragment (denoted here “rTCP₉₆”) corresponding to the C-terminal fragment
105 cleaved out from thrombin by HNE (Fig. S1A–B). Circular dichroism (CD)
106 spectrometry analysis of rTCP₉₆ yielded secondary structure characteristics
107 compatible with the corresponding thrombin region (similar to the B4 peptide).
108 Furthermore, *in silico* modeling studies showed that an rTCP₉₆ structure analogous to
109 the structure of the B4 chain of thrombin adopts a stable fold, with minimal structural
110 drift over extended timescales, comparable with the X-ray structure of γ -thrombin,
111 exhibiting compatible secondary structural content (Table S1 and Methods). Purified
112 rTCP₉₆ was subjected to heparin-affinity chromatography and was found to elute at a
113 similar salt strength as human γ -thrombin (Fig. S1C), compatible with a functional
114 (heparin-binding) activity of rTCP₉₆. Consistent with previous findings of endogenous
115 11-kDa TCP (13), we found that the recombinant form was antimicrobial against *E.*
116 *coli* in a gel-overlay assay. rTCP₉₆ also demonstrated antibacterial effects in radial
117 diffusion assays (RDAs) against *E. coli* and *P. aeruginosa* and viable count assays
118 (VCAs) against *E. coli* (Fig. S1D–H). The results demonstrate that rTCP₉₆, like the
119 native form, and similarly to GKY25 comprising the C-terminal 25 amino acids of
120 rTCP₉₆, kills Gram-negative bacteria *in vitro in the physiological concentration range*
121 *0.5 - 3 μ M*. As GKY25 dose-dependently induces hemolysis, we explored whether
122 TCPs could permeabilize human erythrocytes as well, but we did not detect any such
123 effects (Fig. S1I).

124 **TCPs interact with LPS.** Based on these findings, we next explored possible LPS-
125 rTCP₉₆ interactions and the structural implications of these interactions. Ellipsometry
126 analysis of surface interactions revealed significant binding already at concentrations
127 of 1–2 μM, for both rTCP₉₆ and GKY25 to surface-immobilized *E. coli* LPS, whereas
128 the negative control IVE25 displayed much lower binding (Fig. 1A). As can be seen
129 in Figure S1J, kinetics measurements of LPS binding showed comparable binding
130 kinetics for rTCP₉₆ and GKY25, both displaying an initial mass-transport-limited
131 phase, ranging less than ~200s, followed by a considerably slower binding, most
132 likely as a consequence of structural re-arrangements in the LPS layer on peptide
133 binding. Analogously, microscale thermophoresis (MST), a highly sensitive
134 technique probing interactions between components in solution, demonstrated
135 interactions of fluorescence-labeled rTCP₉₆ with *E. coli* LPS, with a K_D of 3.3 ± 1.8
136 μM (Fig. 1B). Furthermore, in a slot blot assay, using biotin-labeled *E. coli* LPS and
137 immobilized rTCP₉₆, we observed binding of LPS to rTCP₉₆, which was eradicated by
138 the addition of heparin (Fig. S1K). Since heparin binds to a region situated at the C-
139 terminus of the thrombin molecule, which comprises a part of the exosite II site (16),
140 these results indicate that the C-terminal helical end of rTCP₉₆ binds to LPS.

141

142 **LPS induces aggregation of TCPs.** Above observations were substantiated using CD
143 spectrometry, and we found that LPS induced a helical conformation in the 25mer
144 thrombin-derived C-terminal peptide GKY25, consistent with findings of previous
145 studies (10, 17). For comparison, an increase in β-sheet content was observed for
146 rTCP₉₆ after 30 min of incubation with LPS (Fig. 1C). Thioflavin T (ThT) has
147 become amongst the most widely used “gold standards” for selectively staining and
148 identifying amyloid fibrils characterized by β-strand-like interactions (18, 19). Unlike

149 the results observed for GKY25 after the addition of LPS, a significant increase in
150 ThT staining was noted after the addition of LPS to rTCP₉₆, (Fig. 1D), which is
151 consistent with CD data on β -sheet content (Fig. 1C). LPS-induced aggregation of
152 TCP₉₆ was inhibited by an excess of the peptide GKY25 (Fig. S2A). Moreover, LPS-
153 induced ThT binding was observed using a dose range of 1-10 μ M rTCP₉₆ in Tris
154 buffer and in presence of 1% citrated plasma (Fig. S2B). Likewise, LPS induced the
155 formation of amorphous aggregates of rTCP₉₆, of sizes 1–3 μ m, as demonstrated by
156 negative-stain transmission electron microscopy (TEM; Fig. 1E). Furthermore,
157 rTCP₉₆ was added to a buffer containing citrated plasma. Again, we observed similar
158 LPS-induced aggregation that yielded aggregated forms with sizes ranging from 0.5–
159 30 μ m (Fig. 1E). Moreover, co-aggregation of rTCP₉₆ with LPS was confirmed by
160 detection of significant differences in the hydrodynamic radii using dynamic light
161 scattering (Fig. S2C). Using CD spectrometry, ThT binding assay, and dynamic light
162 scattering (DLS) we did not detect a significant aggregation of pure rTCP₉₆ for a time
163 period up to 2 h, which contrasted to the LPS-induced aggregation, observed already
164 after an incubation period of 10 min (Fig. S2D-F).

165 Although rTCP₉₆ mimicked the antibacterial effects of native human TCP, it may be
166 argued that possible differences in folding patterns between the recombinant and
167 endogenous forms could have influenced the observed aggregation of the recombinant
168 peptide. To address this issue, we conducted CD, ThT, and TEM experiments
169 utilizing two fragmented thrombin forms containing TCPs in the form of HNE-
170 digested thrombin or γ -thrombin. The latter is a product of autoproteolysis and
171 contains a C-terminal peptide that is very similar to the HNE-generated fragment (9,
172 20). In all cases, the results using these endogenous TCPs were consistent with those

173 obtained with rTCP₉₆, and no significant aggregation was observed for intact
174 thrombin (Fig. 3F-I).

175

176 **Molecular simulations of the TCP-LPS interaction.** Next, we performed *in silico*
177 analyses of the TCP-LPS interaction using both atomic-resolution and CG molecular
178 dynamics simulations. These simulations allowed us to assess the fold stability of the
179 11-kDa TCP structure, its conformational changes compared with those of intact
180 thrombin, as well as the interaction modes of LPS with TCP. Our analysis revealed a
181 newly exposed amphipathic helix, comprising residues 80–96, buried within intact
182 thrombin. The hydrophobic portion of this amphipathic helix was observed to interact
183 with a sheet region (residues 46–60); we also found that the hydrophobic portion was
184 in a preferred interaction site for the lipid tails of LPS (Fig. 2A). We observed a twist
185 in the β -sheet region in the absence of LPS that enabled the formation of a cluster of
186 hydrophobic residues comprising of F52, Y57, M59, F81, W86, and F94 (Fig. 2A).
187 Therefore, interactions with LPS may enable the relaxation of the sheet twist and
188 accordingly explain the observed increase in β -content in the CD spectra. Coarse-
189 grained models provide a pseudo-atomistic description of the system whilst enabling
190 longer time- and length-scales to be attained, thereby enabling us to study the
191 spontaneous self-assembly of TCP and LPS (Fig. 2B, S2 and Movie S1). These
192 simulations revealed a significantly increased propensity of TCPs to aggregate in the
193 presence of LPS (Fig. 2B and C). Pairwise distance analysis (Fig. 2C) indeed revealed
194 that the aggregation coincides with the preferred LPS binding sites on TCP (Fig. 2A).
195 Furthermore, inspection of the resultant aggregates revealed that LPS intercalates in
196 the TCP clusters and thereby facilitates intermolecular interaction (Fig. 2C, right
197 panel). Our *in silico* results thus correspond elegantly to the experimental data

198 presented above and highlight the unique capabilities of TCPs for structural
199 modulation and specific LPS-mediated intermolecular interactions that enable their
200 aggregation.

201

202 **TCPs mediate bacterial aggregation and phagocytosis.** Considering that rTCP₉₆
203 and degraded thrombin (10) exert antibacterial effects, we next explored whether
204 rTCP₉₆ could form aggregates together with Gram-negative (LPS-containing)
205 bacteria. Indeed, incubation of rTCP₉₆ with *E. coli* yielded similar amyloid-like ThT-
206 positive amorphous aggregates, as previously identified after the addition of LPS (Fig.
207 3A). Using negative-stain TEM, we identified aggregated bacteria, and we observed
208 signs of membrane perturbations in rTCP₉₆-treated cells only (Fig. 3B). The
209 impermeable marker FITC was taken up by these bacterial aggregates (Fig. 3C),
210 indicative of bacterial killing, which is consistent with the antibacterial effects by
211 rTCP₉₆ noted above (Fig. S1D–F). Figure 3D illustrates that while both GKY25 and
212 rTCP₉₆ were able to induce uptake of FITC, only rTCP₉₆ significantly increased the
213 aggregation of *E. coli* ($p < 0.01$). In order to explore the functional significance of
214 TCP-mediated aggregation, we hypothesized that aggregate formation was linked to
215 phagocytic clearance. Indeed, we found that fluorescent *E. coli* particles, aggregated
216 with rTCP₉₆, were taken up by the macrophage cell line RAW 264.7. Notably, rTCP₉₆
217 at 0.5 μM yielded a roughly 25% increase in phagocytosis compared with *E. coli*
218 particles only ($p < 0.01$; Fig. 3E). Phagocytized fluorescent *E. coli* particles (green
219 color), aggregated with rTCP₉₆ (visualized using fluorescently labeled antibodies),
220 were also detected in RAW 264.7 cells using fluorescence microscopy (Fig. 3F and
221 S3). Taken together, these results indicate that both the rTCP₉₆ and native TCPs are

222 able to aggregate and form amyloid structures, and that this phenomenon is promoted
223 in the presence of LPS or bacteria and followed by phagocytic uptake.

224

225 **TCPs are present in wound fluids and aggregate with *E. coli* and LPS.** Earlier
226 studies have shown that thrombin binds to fibrin clots and that fibrin acts as a
227 reservoir for active thrombin (21). Furthermore, human neutrophils release elastase
228 during the initial phases of wound healing, and the enzyme may cleave thrombin
229 present in soluble form, as well as when immobilized in fibrin (10). As expected, and
230 compatible with our previous findings, wound fluids from patients with non-infected
231 surgical wounds contained several TCPs (Fig. 4A). **The concentrations of endogenous**
232 **TCPs (~11 kDa) in wound fluids have been estimated from calibration curves using**
233 **Western blot analysis. The calculated concentrations of peptides were from 0.6 to 2.7**
234 **μM (Fig S2G).** As shown above, rTCP₉₆ forms aggregates in a plasma environment
235 (Fig. 1D). To address whether endogenous TCPs could also form aggregating amyloid
236 structures, we incubated human wound fluid with LPS and analyzed aggregate
237 formation. Similar to the *in vitro* studies described above, we were able to identify
238 LPS-induced aggregates in the wound fluids. By utilizing gold-labeled antibodies, we
239 detected C-terminal epitopes in these structures (Fig. 4B). When these experiments
240 were repeated with *E. coli*, we observed a significant aggregation with TEM after the
241 addition of the bacteria to the wound fluid (Fig. 4C). These results were supported by
242 confocal microscopy data (Fig. 4D and E), where the same initial experimental setup
243 was used, followed by specific staining for TCPs (red) and amyloids (green).
244 Therefore, TCP-containing aggregates were induced after the addition of LPS (Fig.
245 4D) or *E. coli* (Fig. 4E), yielding aggregates containing TCPs that overlapped with
246 ThT staining (green), thereby indicating the formation of TCP-containing amyloids.

247 **TCPs are found with aggregated LPS *in vivo*.** Non-healing venous ulcers are
248 characterized by the presence of bacteria accompanied by the activation of neutrophils
249 and the release of HNE (22, 23). We accordingly investigated the production of TCPs
250 in fibrin slough from a patient with such a venous ulcer; we also studied the fluid
251 from a wound dressing covering the ulcer. As shown in Figure 4F, we detected TCPs
252 in both the fibrin and the wound exudate. We next investigated the fibrin slough from
253 non-healing ulcers from two patients to search for the presence of TCP-LPS
254 aggregates via negative-stain TEM utilizing specific gold-labeled antibodies. The
255 antibodies against TCPs were detected by anti-rabbit IgG with labeled gold particles
256 10 nm in diameter (blue dots); for the detection of LPS we used IgG anti-LPS labeled
257 with 5-nm gold particles (red dots, Fig. 4G). A colocalization of TCPs (10 nm
258 particles) and LPS (5 nm particles) was observed in both patient samples, in the range
259 30-600 nm, with a peak in the lower range (below 50 nm) where the pair cross-
260 correlation function (PCCF) exceeded ~ 2 (Fig. S2H). Antigens which do not cross-
261 correlate have no PCCF peak in any interval, and the value is fluctuating around 1
262 (24).

263

264 **Discussion**

265 Endotoxin, a highly proinflammatory substance, as well as bacteria, need to be
266 contained and controlled, and the present work discloses a simple but effective
267 mechanism by which aggregation prone TCPs facilitate this clearance - of relevance
268 for control of infection and inflammation during wounding. Apart from revealing a
269 novel role for thrombin as a source for endotoxin- and bacteria-aggregating peptides
270 during wounding, our results also raise interesting perspectives on the roles of, and
271 relation between, antimicrobial and amyloidogenic peptides. It is clear that various

272 peptides from these two classes are able to bind and damage bacterial and eukaryotic
273 cell membranes. Indeed, it has been proposed that some peptides that are
274 simultaneously antimicrobial and amyloidogenic have separate sequence motifs
275 encoding these two activities (25). Considering the observation that the shorter TCP
276 GKY25 does not form any aggregates, this would imply that the sequence responsible
277 for the aggregation behavior, and β -sheet formation, is found upstream of the GKY25
278 sequence, which is in agreement with *in silico* predictions. Although structurally
279 separate, our data indicate that the antimicrobial and amyloidogenic properties are
280 interdependent, indeed connecting the antimicrobial and LPS-aggregating functions
281 within one single molecule.

282

283 A controlled and targeted proteinase action is crucial during wounding. Thrombin,
284 initially formed by selective proteolysis by coagulation factor X, mediates fibrinogen
285 degradation and clot formation (7) but also exerts other physiologic functions in
286 innate defense and hemostasis (7) (Fig. 5). As previously reported, subsequent
287 proteolysis leads to formation of smaller TCPs of about 2 kDa with anti-endotoxic
288 functions (10, 14, 15) (Figure 5). Interestingly, *Pseudomonas aeruginosa* "hijacks"
289 this mechanism by release of bacterial elastase, which cleaves out a TCP of 21 amino
290 acids, thereby enabling modulation and circumvention of host responses (14). In
291 many aspects, such TCPs act as "classical" host defense peptides like LL-37 (26),
292 which also binds to LPS, leading to inhibition of NF- κ B activation. The herein
293 presented work on LPS and bacteria-induced aggregation of TCPs therefore adds a
294 new, and previously undisclosed, dimension to the role of thrombin (Fig. 5).
295 Furthermore, the finding that thrombin fragments, including ~11 kDa TCPs are
296 present in acute, sterile wound fluids, together with the rapid aggregation of LPS and

297 bacteria observed in these wounds fluids *ex vivo*, indicates a fundamental role for
298 aggregation and amyloid formation in the containment and rapid clearance of
299 endotoxins and invading microbes.

300

301 This link between host defense and aggregation also suggests that chronic
302 inflammatory states may lead to dysfunctional activation of such host defense
303 pathways. Indeed, amyloidogenic aggregates are implicated in a broad range of
304 protein misfolding diseases such as Parkinson's, Huntington's and Alzheimer's disease
305 (AD). Moreover, amyloidogenic amyloid- β -peptide variants have been shown to exert
306 antimicrobial activity (27, 28). Furthermore, peptides derived from the disulfide-
307 constrained loop region of human β -amyloid precursor protein and the N-terminus of
308 human prion protein are antimicrobial (29, 30). Interestingly, neutrophils have
309 recently been implicated in the pathogenesis of amyloid deposits in AD of humans as
310 well as in mouse AD models (31), highlighting the importance of peripheral innate
311 immunity for amyloid formation. Thus, hypothetically, as both thrombin and
312 neutrophils are increased in AD (32, 33), high inflammatory activity could lead to
313 degradation of thrombin and generation of amyloidogenic complexes.

314 In summary, we have revealed here a previously unknown host defense action of
315 proteolysed thrombin and its fragments, based on LPS-induced
316 aggregation/scavenging, clearance, and microbial killing. Our findings add new
317 information to the broad spectra of thrombin functions and provide a novel link
318 among the coagulation system, host defense, and LPS- and bacteria-induced
319 aggregation and amyloid formation.

320

321

322 **Materials and Methods**

323

324 **Ethics statement.** The use of human wound materials was approved by the Ethics
325 Committee at Lund University (LU 708-01, LU 509-01). Informed consent was
326 obtained from all of the donors, and the use of human blood was approved by the
327 Ethics Committee at Lund University, Lund, Sweden (permit no. 657-2008).

328

329 **Biological materials.** Fibrin sloughs from chronic non-healing wounds were
330 collected using a sterile spatula and immediately either fixed in the solution for
331 electron microscopy or frozen at -20°C for later extraction for sodium dodecyl sulfate
332 polyacrylamide gel electrophoresis (SDS-PAGE). Sterile wound fluids were obtained
333 from surgical drainages after surgery. The collection of samples was performed 24
334 hours and 24–48 hours after surgery. The wound fluids were centrifuged, aliquoted,
335 and stored at -20°C.

336

337 **Microorganisms.** The *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa*
338 ATCC 27853 bacterial strains were purchased from LGC (U.K.).

339

340 **Cells.** RAW 264.7 cells (American TYPE Culture Collection, USA) were cultured in
341 DMEM (HyClone, GE Healthcare Life Science, USA) supplemented with 10% (v/v)
342 heat-inactivated FBS (FBSi; Invitrogen, USA) and 1% (v/v) antibiotic-antimycotic
343 solution (AA; Invitrogen).

344

345 **Peptides.** The thrombin-derived peptides GK Y25
346 (GKYGFYTHVFR LKKW IQKVIDQFGE) and IVE25

347 (IVEGSDAEIGMSPWQVMLFRKSPQE) were synthesized by Biopeptide Co, Inc.
348 (USA). We confirmed the purity (over 95%) via mass spectral analysis (MALDI-TOF
349 Voyager, USA).

350

351 **Digestion of α -thrombin and Western blotting.** Digestion of α -thrombin (10 μ M;
352 Innovative Research, Inc., USA) was performed for 3 hours at 37°C using 0.8 μ g/ml
353 HNE (Calbiochem, USA). The protein and peptides were separated by electrophoresis
354 on a 10–20% Tricine gel (Novex, Life Technologies, USA) and subsequently
355 transferred to a PVDF membrane using the Trans-Blot Turbo (Bio-Rad, USA).
356 Polyclonal rabbit antibodies against the C-terminal thrombin epitope VFR17
357 (VFRLKKWIQKVIDQFGE; diluted 1:800, Innovagen AB, Sweden), followed by
358 porcine anti-rabbit HRP conjugated antibodies (1:1000, Dako, Denmark), were used
359 to detect the C-terminal epitopes of thrombin. The C-terminal peptides were
360 visualized using Chemiluminescent substrates (Thermo Scientific, USA) using a
361 ChemiDoc MP imaging system (Bio-Rad).

362

363 **Purification of rTCP₉₆.** A bacterial expression system consisting of pGEX plasmid
364 in *Escherichia coli* strain *BL21 codon plus (DE3) RIPL* (Invitrogen) was used to
365 produce the rTCP₉₆. We cultivated the bacteria in LB broth (Sigma-Aldrich, USA)
366 supplemented with 34 μ g/ml chloramphenicol and 100 μ g/ml carbomycin. IPTG (400
367 μ M; VWR, USA), added at the mid-log phase, was used to induce peptide production
368 in the bacterial system. The rTCP₉₆ peptides were extracted and purified by
369 immobilized metal affinity chromatography (Ni-NTA Agarose, Invitrogen) under
370 denaturing conditions (8 M Urea, 10 mM Tris, pH 7.4), extensively washed with 20
371 mM of imidazole in 8 M Urea, 10 mM Tris, pH 7.4, and then eluted by stepwise

372 increasing concentrations of imidazole (200 mM). rTCP₉₆ was desalted in 10 mM
373 Tris, pH 7.4 by step-wise dialysis and concentrated using a 3-kDa molecular weight
374 cut-off Amicon ultracentrifugal filter device (Millipore, Germany) and stored at 4°C
375 prior to use (34). Peptide purity was confirmed via Tricine gel electrophoresis
376 followed by Gel Code Blue Safe Protein staining (Thermo Scientific) and Western
377 blotting, as noted above. The protein concentration was determined by Nanodrop (ND
378 1000, Thermo Scientific).

379

380 **Heparin-affinity chromatography.** We subjected rTCP₉₆ and γ -thrombin (10-30 μ g)
381 to fast protein liquid chromatography (ÄKTA purifier; GE Healthcare) using a HiTrap
382 1 ml Heparin HP column (GE Healthcare, Sweden). After injection, the samples were
383 eluted with a linear gradient of 0–1M NaCl in 10 mM Tris, pH 7.4.

384

385 **Extraction of thrombin fragments from fibrin sloughs and a wound dressing.**

386 The fibrin sloughs were freeze-dried using the freeze-drying system Freezone Plus 6
387 (Labconco, USA). The freeze-dried samples of the fibrin sloughs (\approx 7 mg) and 1 cm²
388 of wound dressing (Allevyn, USA) were incubated with 300 μ l of SDS loading buffer
389 and homogenized using a MagNA lyser homogenizer (Roche, USA). The
390 homogenized samples were boiled for 10 min at 95°C. We analyzed the
391 protein/peptide composition of the extracts via electrophoresis and then Western
392 blotting, as noted above.

393

394 **Viable count assay.** To determine the antibacterial activity of rTCP₉₆, we used *E. coli*
395 ATCC 25922. The bacteria were grown to mid-logarithmic phase in 10 ml of Todd-
396 Hewitt (TH) medium. The bacteria were centrifuged, washed, and suspended in 10 ml

397 of 10 mM of Tris buffer, pH 7.4. Next, *E. coli* ATCC 25922 (50 μ l, 2×10^6 colony
398 forming units; cfu/ml) were incubated with 3–6 μ M of rTCP₉₆, GKY25, or buffer
399 control (10 mM Tris buffer, pH 7.4) for 2 hours at 37°C. Dilution series of the
400 incubated samples were plated on TH agar plates, incubated overnight at 37°C, and we
401 calculated the cfu.

402

403 **Radial diffusion assay.** We used *E. coli* ATCC 25922 and *P. aeruginosa* ATCC
404 27852 for the RDA. The bacteria were grown to mid-log phase in 10 ml of TH
405 medium, spun down, washed, and suspended in 10 ml of 10 mM Tris buffer, pH 7.4.
406 This step was followed by the addition of bacteria (4×10^6) to 15 ml of under-lay
407 agarose gel, consisting of 0.03% TH media, 1% (w/v) low-electroendosmosis-type
408 (EEO) agarose (Sigma-Aldrich), and 0.02% (v/v) Tween 20 (Sigma-Aldrich). The
409 underlay was poured into a 144-mm-diameter petri dish. After solidification, 4-mm-
410 diameter wells were punched in the underlay, which were subsequently loaded with
411 6 μ l of 10 μ M of GKY25 or rTCP₉₆ in 10 mM Tris buffer, pH 7.4. The plates were
412 thereafter incubated for 3 hours at 37°C. Molten over-lay gel (15 ml, 6% TH, and 1%
413 low-EEO agarose in water) was added to the plate. We measured the antimicrobial
414 activity of the peptides by measuring the radius of the clearing zone surrounding the
415 wells after 18–24 hours of incubation at 37°C.

416

417 **Gel-overlay assay.** A gel-overlay assay was performed on duplicate samples that
418 were run on a non-denaturing acid urea (AU-PAGE) gel in 5% acetic acid at 100 V
419 for 75 min using reversed polarity. Bacterial pre-cultures were grown overnight in 10
420 ml of TH broth, inoculated the subsequent day and grown until their optical density
421 (OD) reached 0.4. The bacteria were washed and the pellet re-suspended in 10 mM

422 Tris, pH 7.4. The bacteria (4×10^6) were added to 15 ml of melted underlay agarose
423 (10 mM Tris, pH 7.4, 0.03% of TH broth, 1% of agarose type, and 1% low-EEO
424 agarose) and poured into petri dishes. One AU gel was stained with Coomassie
425 brilliant blue and the other was washed three times with 10 mM Tris, pH 7.4 for 4 min
426 and then placed on the top of the underlay gel, followed by incubation for 3 hours at
427 37°C. Overlay agar (15 ml) was poured over underlay and left to solidify. The
428 inhibition zones were measured using an electronic digital callipers (Perel, Belgium)
429 after 16 hours of incubation at 37°C.

430

431 **Slot-blot assay.** We used a slot-blot assay to detect the interaction between rTCP₉₆
432 and LPS. rTCP₉₆ and GKY25 (2 and/or 5 µg per well) were bound to nitrocellulose
433 membrane (Hybond-C, GE Healthcare, Biosciences) after pre-soaking in 10 mM Tris,
434 pH 7.4. The membrane was incubated in the blocking solution (2% BSA in PBS, pH
435 7.4) for 1 hour at room temperature and subsequently incubated with 20 µg/ml
436 biotinylated LPS (LPS-EB Biotin, InvivoGen, USA) in PBS for 1 hour at room
437 temperature. Next, the membranes were washed three times for 10 min in PBS and
438 incubated with streptavidin-horseradish peroxidase conjugate (Thermo Scientific).
439 Binding was detected using peroxide solution and a luminol/enhancer solution (1:1
440 v/v) (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific). To test
441 for competitive inhibition of peptide binding to LPS, we also performed binding
442 studies in the presence of unlabeled heparin (6 mg/ml).

443

444 **Fluorescence microscopy.** FITC is a fluorescent probe able to permeate the
445 membranes of dead bacteria and bind to bacterial DNA, which is detected as a green
446 fluorescent signal. *E. coli* ATCC 25922 were grown to mid-logarithmic phase in 10 ml

447 of TH medium. The bacteria were centrifuged, washed, and suspended in 10 ml of 10
448 mM Tris, pH 7.4. Next, *E. coli* ATCC 25922 (100 μ l; 1×10^7 cfu/ml) were incubated
449 with 10 μ M of GK Y25, rTCP₉₆ or control (10mM, Tris, pH 7.4) for 1 hour at 37°C.
450 The microorganisms were incubated on poly (L-lysine)-coated glass slides via
451 incubation for 45 min at 37°C. Next, 200 μ l of FITC (6 μ g/ml) was added to the top of
452 each slide. The samples were thereafter fixed with 2% of paraformaldehyde for 15 min
453 at 4°C and 45 min at room temperature. The cover slides were mounted on microscope
454 slides with fluorescent mounting media (Daco, USA). A Nikon Eclipse TE300
455 inverted fluorescent microscope (Nikon, Japan) supplied with a Hamamatsu C4742-95
456 cooled CCD camera (Hamamatsu, Japan) and a Plan Apochromat x100 objective
457 (Olympus, USA) were employed to acquire images of the FITC-stained bacteria. We
458 used imaging software NIS-elements 3.1 (Nikon) for the image acquisition and
459 processing.

460

461 **Thioflavin T dye binding assays.** Amyloid formation was determined using the dye
462 Thioflavin T (ThT). Thioflavin T preferentially binds to the β -sheet structures of
463 amyloidogenic proteins/peptides. For the assay, rTCP₉₆ (10 μ M), GK Y25 (10 μ M),
464 alpha thrombin (10 μ M \pm HNE), γ -thrombin (10 μ M), LPS (100 μ g/ml), or buffer only
465 (10 mM Tris, pH 7.4) were incubated with LPS for 30 min at 37°C. For examination
466 of time dependence of the aggregation, rTCP₉₆ (10 μ M) was incubated for 10, 30, 60
467 and 120 minutes at 37°C in absence or presence of LPS in 10 mM Tris, pH 7.4. For
468 examination of concentration dependence of the aggregation, rTCP₉₆ (0.1, 0.5, 1, 2, 5
469 and 10 μ M) was incubated for 30 minutes at 37°C in absence or presence of LPS in
470 10 mM Tris, pH 7.4. In one experiment, the buffer was supplemented with 1%
471 citrated plasma. For evaluation of effects of GK Y25 on the aggregation, GK Y25 (1, 5,

472 10 and 20 μM) was added to rTCP₉₆ (10 μM) and LPS (100 $\mu\text{g}/\text{ml}$) in 10 mM Tris, pH
473 7.4, followed by a 30 min incubation period. Two hundred μl of the materials were
474 incubated with ThT (final concentration: 10 μM) for 15 min in the dark (ThT stock
475 was 1 mM stored in the dark at 4°C in glycine 0.1 M, pH 8.5). We measured ThT
476 fluorescence using a VICTOR3 Multilabel Plate Counter spectrofluorometer
477 (PerkinElmer, USA) at an excitation of 450 nm, with excitation and emission slit
478 widths of 10 nm. The baseline (10 mM Tris buffer, LPS or HNE) was subtracted from
479 the signal of each sample (18).

480

481 **Circular dichroism.** We performed circular dichroism (CD) measurements on a
482 Jasco J-810 spectropolarimeter (Jasco, USA) equipped with a Jasco CDF-426S Peltier
483 set to 25°C. The peptides/proteins were diluted to 10 μM in Tris buffer (10 mM, pH
484 7.4) and incubated with 10 μM of LPS for 1 hour at 37°C, placed in a 10 mm quartz
485 cuvette and, after extensive purging with nitrogen, scanned over the wavelength
486 interval 200–260 nm (scan speed: 20 nm/min). We calculated the averages of five
487 scans for each sample. For examination of time dependence, rTCP₉₆ (10 μM) was
488 incubated for 10 and 120 minutes at 37°C in absence or presence of LPS (100 $\mu\text{g}/\text{ml}$)
489 in 10 mM Tris, pH 7.4. The baseline (10 mM Tris buffer, LPS or HNE) was
490 subtracted from the spectra of each sample.

491

492 **Transmission electron microscopy.** We visualized the aggregates formed by rTCP₉₆
493 in plasma alone, or in the presence of LPS or *E. coli*, of HNE-treated α -thrombin (10
494 μM) or γ -thrombin alone (10 μM) after incubation with LPS using TEM (Jeol Jem
495 1230; Jeol, Japan) in combination with negative staining. The samples were adsorbed
496 onto carbon-coated grids for 60 s and stained with 7 microliters of 2% uranyl acetate

497 for 20 s. The grids were rendered hydrophilic via glow discharge at low pressure in
498 air.

499 Furthermore, we used TEM to study the aggregation of endogenous thrombin
500 fragments in acute wound fluids. Polyclonal rabbit antibodies (against the VFR17
501 epitope) were labeled with gold particles 20 nm in diameter and subsequently added
502 to acute wound fluids and incubated for 30 min at 37°C. We also performed TEM
503 analysis of TCPs and LPS in fibrin sloughs by incubating the material with gold-
504 labeled VFR17 antibodies followed by incubation with gold-labeled anti-rabbit IgG
505 (10 nm). Electron micrographs of the fibril sloughs were captured using an electron
506 microscope Philips/FEI CM100 (Philips/FEI, USA). The detection of LPS was
507 performed using IgG against LPS with labeled gold particles 5 nm in diameter.
508 Analysis of the distribution and possible colocalization of large and small gold
509 particles, representing TCPs and LPS, respectively, was performed using the plugin
510 “Gold” in the Ellipse program (<http://nucleus.img.cas.cz/gold/>) (24).

511

512 **Phagocytosis assay.** The macrophage cell line RAW 264.7 (passage 8, 9, and 10),
513 grown in DMEM media with 10% (v/v) of FBSi and 1% (v/v) AA, was seeded in 96-
514 well tissue culture plates (8×10^4 cells per well) overnight at 37°C in a 5% CO₂
515 atmosphere. pHrodo Green *E. coli* BioParticles (Life Technologies, USA) were re-
516 suspended in 2 ml Hanks’ Balanced salt solution (Life Technologies, UK) and pre-
517 treated with 1.0 and 0.5 μM of rTCP₉₆ in 10 mM of Tris for 1 hour at 37°C. The pre-
518 treated suspension of *E. coli* BioParticles was added to the adherent RAW cells. To
519 analyze phagocytosis, the particles were incubated with the cells for 1.5 hours at
520 37°C. We then measured fluorescence using a VICTOR3 Multilabel Plate Counter
521 spectrofluorometer (PerkinElmer, USA) at excitation/emission wavelengths of

522 485/535 nm. The baseline uptake (of only *E. coli* BioParticles) was subtracted from
523 the signal of each sample.

524

525 **Confocal microscopy.** We performed ThT staining to visualize amyloid formation of
526 10 μM rTCP₉₆ and endogenous TCPs in selected acute wound fluids, which were
527 induced by LPS and/or *E. coli* ATCC 25922. The bacterial suspension was prepared
528 as described above for RDA and VCA. The LPS/*E. coli*-treated samples of acute
529 wound fluids/rTCP₉₆ were fixed and washed as described above (FITC staining). The
530 samples were subsequently incubated with 200 μl of ThT (25 μM) on slides for 30
531 min at 37°C. The primary antibodies against the TCP sequence were added to the
532 samples containing wound fluid, followed by the washing step and the addition of
533 secondary antibodies. The incubation parameters were adopted from the Western
534 blotting technique (see above), and the incubation duration of each antibody was 30
535 min at 37°C. The cover slides (Thermo Scientific, Germany) were mounted on
536 microscope slides with fluorescent mounting media (Molecular probes, Life
537 Technologies, USA).

538 RAW 264.7 cells (200000 cells/ml) were seeded on round cover glasses and
539 incubated overnight to enable adherence. The next day, the *E. coli* particles were pre-
540 incubated with 1 μM TCP as described in the phagocytosis assay. Fixed cells were
541 permeabilized with 0.5% Triton diluted in PBS for 2 min at RT. The following
542 staining method to visualize TCP was performed as described above. The samples
543 were mounted with ProLong Gold with DAPI (Life Technologies, USA) to stain the
544 nuclei.

545 We examined the mounted samples using an LSM 700 laser-scanning confocal
546 microscope (Zeiss, Germany) with excitation wavelengths of 488 and 568 nm and a

547 C-Apochromat 63x/1.20W korr M27 glycerol immersion objective. Images were
548 collected using Zen 2012 software and analyzed using ImageJ software (version
549 1.49q).

550

551 **Hemolysis assay.** Fresh citrated venous blood from healthy donors (2 females, 1
552 male) was centrifuged at 250g, and the pellet was washed three times with PBS. Next,
553 the pellet was diluted five times, and 5 μ l of this solution was transferred to each well
554 of a 96-well plate containing 195 μ l of rTCP₉₆ (0.1, 1, 2, 5, and 10 μ M) in PBS. After
555 1 hour of incubation at 37°C and 5% CO₂, the plate was centrifuged at 800g. Next,
556 150 μ l of each sample was transferred to a flat-bottom 96-well plate and the
557 absorbance at 450 nm was measured. The results are expressed as a percentage of the
558 erythrocyte lysis compared with the positive control (2.5% Tween-20). Values below
559 10% are regarded as non-hemolytic.

560

561 **Ellipsometry.** Peptide adsorption was studied *in situ* by null ellipsometry (35) using
562 an Optrel Multiskop (Optrel, Germany) equipped with a 100 mW Nd:YAG laser (JDS
563 Uniphase, USA). All of the measurements were carried out at 532 nm and an angle of
564 incidence of 67.66° in a 5 ml cuvette under stirring (300 rpm). Both the principles of
565 null ellipsometry and the procedures used have been previously described in the
566 literature(36). In brief, by monitoring the change in the state of polarization of light
567 reflected at a surface in the absence and presence of an adsorbed layer, the mean
568 refractive index (n) and layer thickness (d) of the adsorbed layer can be obtained.
569 Based on the thickness and the refractive index, we calculated the adsorbed amount
570 (Γ) using the following equation:

571
$$\Gamma = \frac{(n - n_0)}{dn/dc} d \quad (35)$$

572

573 where dn/dc ($0.154 \text{ cm}^3/\text{g}$) is the refractive index increment and n_0 is the refractive
574 index of the bulk solution. Corrections were routinely applied to the bulk refractive
575 index to account for changes in temperature and excess electrolyte concentration.

576 LPS-coated surfaces were obtained by adsorbing *E. coli* LPS to methylated silica
577 surfaces (surface potential -40 mV and contact angle 90° (37)) from 5 mg/ml LPS
578 stock solution in water at a concentration of 0.4 mg/ml in 10 mM Tris, $\text{pH } 7.4$. This
579 LPS concentration corresponds to saturation in the LPS adsorption isotherm
580 ($1.48 \pm 0.38 \text{ mg/m}^2$) under these conditions. Non-adsorbed LPS was removed by
581 rinsing with Tris buffer at 5 ml/min for a period of 30 min and allowing to buffer to
582 stabilize for 20 min . Peptide addition was subsequently performed to 0.01 , 0.1 , 0.5 ,
583 and $1 \text{ }\mu\text{M}$, and adsorption monitored for at least one hour after each addition. All of
584 the measurements were performed in at least triplicate at 25°C .

585

586 **Molecular dynamics simulations.** The crystal structure of human γ -thrombin was
587 retrieved from the Protein Data Bank (PDB) (38). The 11-kDa TCP was modeled
588 using a single chain of the γ -thrombin structure. The extracted chain was placed in a
589 cubic box of TIP3P water molecules at a salt concentration of 0.1 M . An atomistic
590 model of the 11-kDa TCP was derived using the Amber force field ff14SB (39). The
591 11-kDa TCP was simulated for 100 ns in the NpT ensemble at 300 K and 1 bar to
592 assess the stability of the fold. In parallel, a CG model of TCP was derived from the
593 same starting structure using the MARTINI force field (40). The CG model was
594 incubated with a single lipid A molecule and simulated for $5 \times 1 \text{ }\mu\text{s}$ to determine the
595 preferential interaction sites of TCP with LPS. Preferential sites comprise of the

596 newly exposed residues 44–62 and 80–96 for the lipid tails of LPS and the residues 1–
597 20 for the polar head of LPS. Next, the TCP molecules were incubated with and
598 without 8 LPS molecules in order to study aggregation behavior. We performed 5 x 1
599 μ s of simulations for both the 8 TCP and the 8 TCP with 8 LPS systems. We
600 calculated the pairwise distances between all of the residues on the TCP molecules
601 and summed them over all of the intermolecular interactions. The resulting average
602 distances reveal increased aggregation at sites that had previously been identified to
603 preferentially interact with LPS.

604

605 ***In silico* modeling of TCP fold stability and secondary structure.** The region
606 corresponding to amino acids 527-622 (prothrombin numbering) was extracted from
607 the structure of full-length thrombin. It was simulated in explicit TIP3P water
608 molecules at a salt concentration of 0.1 M for 1 microsecond using the Amber force
609 field ff14SB (39), and exhibited a stable fold. After equilibration of the N-and C-
610 terminal segments, the backbone RMSD of the core domain with respect to the X-ray
611 structure of gamma-thrombin 0.25 nm respectively. Mean secondary structural
612 contents during the equilibrated simulation period were calculated using STRIDE
613 (10.1093/nar/gkh429) as implemented in *VMD 1.9.2* (PMID: 8744570).

614

615 **Microscale thermophoresis.** We performed MST analysis using a NanoTemper
616 Monolith NT.115 apparatus (Nano Temper Technologies, Germany). We used a
617 Monolith NT Protein labeling kit RED – NHS (Nano Temper Technologies) to label
618 10 μ M of rTCP₉₆ according to the manufacture’s protocol. A constant amount of 1.5
619 μ M of rTCP₉₆ was mixed with increasing concentrations of LPS in Tris buffer (10
620 mM, pH 7.4). Next, 10 μ l of the samples was loaded into standard glass capillaries

621 (Monolith NT Capillaries, Nano Temper Technologies), and we performed the MST
622 analysis (settings for the light-emitting diode and infrared laser were 80%). Labeled
623 IVE25 was added to LPS under the same conditions as above and used as negative
624 control.

625

626 **Dynamic light scattering.** We performed dynamic light scattering (DLS)
627 measurements to measure the hydrodynamic radii of rTCP₉₆, LPS and LPS-rTCP₉₆.
628 Wyatt QELS (Quasi Elastic Light Scattering, Wyatt Technology Corporation, USA)
629 and Dawn EOS (Enhance optical system, Wyatt Technology Corporation) equipped
630 with a temperature-controlled microsampler instrument were used for DLS
631 measurements. We incubated the samples for 1 hour at 37°C under reducing
632 conditions and the scattered light was detected at 18 different angles simultaneously.
633 Before the experiment, all samples were filtered through 0.22 µm pore sized micro-
634 filters (Sartorius, Germany). Aliquots of samples were manually loaded into the flow
635 cell and measured at 37°C. All samples (1 µM of rTCP₉₆, LPS, LPS-rTCP₉₆,
636 respectively) were measured at least 15 times. GK Y25 peptide was used as a negative
637 control and analyzed under the same conditions. For evaluation of time dependence of
638 the aggregation, rTCP₉₆ (1 µM) was incubated for 10, 30, 60 and 120 minutes at 37°C
639 in absence or presence of LPS (10 µg/ml) in 10 mM Tris, pH 7.4. The hydrodynamic
640 radii were analyzed by Astra V software using Zimm modeling.

641

642 **Statistical analysis.** The diagrams of RDA, VCA, ThT, DLS and hemolysis assay are
643 presented as means and standard deviations from at least three independent
644 experiments. We assessed differences in these assays using one-way ANOVA with
645 Dunnett's multiple comparison tests and two-way ANOVA with Sidak's multiple

646 comparison tests. All of the data were analyzed using Graphpad Prism (GraphPad
647 Software, Inc., USA). A p value less than 0.05 was considered to be statistically
648 significant (* p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001).

649

650

651 **Acknowledgements**

652

653 This work was supported by grants from the Swedish Research Council (projects
654 2012-1883 and 2012-1842), the O.E. and Edla Johanssons, Welander-Finsen,
655 Crafoord, Österlund, and Söderberg Foundations, the Swedish Foundation for
656 Strategic Research, the Knut and Alice Wallenberg Foundation, The Swedish
657 Government Funds for Clinical Research (ALF), and the medical faculty of Lund
658 University. We thank Maria Baumgarten and Ms. Lisa-Britt Wahlberg for excellent
659 technical assistance with the TEM preparation and ellipsometry, respectively. We
660 acknowledge the Lund University Bioimaging Centrum (LBIC) for access to EM
661 facilities. We are indebted to Dr. Sven Kjellström at the Department of Biochemistry
662 and Structural Biology, Center for Molecular and Protein Science, Lund University
663 for verification of the amino acid sequence of rTCP₉₆ via electrospray ionization mass
664 spectrometry. We acknowledge Dr. Vlada Philimonenko from the Microscopy Center
665 – Electron Microscopy CF, IMG AS CR supported by the MEYS CR (LM2015062
666 Czech-BioImaging), for analyses of colocalization of the immunogold labeled EM
667 samples.

668

669 **References**

670

- 671 1. Tennessen JA (2005) Molecular evolution of animal antimicrobial
672 peptides: widespread moderate positive selection. *Journal of Evolutionary*
673 *Biology* 18(6):1387-1394.
- 674 2. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate
675 immunity. *J Leukoc Biol* 75(1):39-48.
- 676 3. Zasloff M (2002) Antimicrobial peptides of multicellular organisms.
677 *Nature* 415(6870):389-395.
- 678 4. Huttner KM & Bevins CL (1999) Antimicrobial peptides as mediators of
679 epithelial host defense. *Pediatric Research* 45(6):785-794.
- 680 5. Kalle M, *et al.* (2013) Proteolytic activation transforms heparin cofactor II
681 into a host defense molecule. *J Immunol* 190(12):6303-6310.
- 682 6. Papareddy P, *et al.* (2014) Antimicrobial effects of helix D-derived
683 peptides of human antithrombin III. *J Biol Chem* 289(43):29790-29800.
- 684 7. Bode W (2006) The structure of thrombin: a janus-headed proteinase.
685 *Semin Thromb Hemost* 32 Suppl 1:16-31.
- 686 8. Davie EW & Kulman JD (2006) An overview of the structure and function
687 of thrombin. *Semin Thromb Hemost* 32 Suppl 1:3-15.
- 688 9. Brower MS, Walz DA, Garry KE, & Fenton JW, 2nd (1987) Human
689 neutrophil elastase alters human alpha-thrombin function: limited
690 proteolysis near the gamma-cleavage site results in decreased fibrinogen
691 clotting and platelet-stimulatory activity. *Blood* 69(3):813-819.
- 692 10. Papareddy P, *et al.* (2010) Proteolysis of human thrombin generates novel
693 host defense peptides. *PLoS Pathog* 6(4):e1000857.
- 694 11. Angus DC & van der Poll T (2013) Severe sepsis and septic shock. *N Engl J*
695 *Med* 369(21):2063.
- 696 12. Kalle M, *et al.* (2012) Host defense peptides of thrombin modulate
697 inflammation and coagulation in endotoxin-mediated shock and
698 *Pseudomonas aeruginosa* sepsis. *PLoS One* 7(12):e51313.
- 699 13. Papareddy P, *et al.* (2010) C-terminal peptides of tissue factor pathway
700 inhibitor are novel host defense molecules. *J Biol Chem* 285(36):28387-
701 28398.
- 702 14. van der Plas MJ, *et al.* (2016) *Pseudomonas aeruginosa* elastase cleaves a
703 C-terminal peptide from human thrombin that inhibits host inflammatory
704 responses. *Nat Commun* 7:11567.
- 705 15. Hansen FC, *et al.* (2015) The Thrombin-Derived Host Defense Peptide
706 GKY25 Inhibits Endotoxin-Induced Responses through Interactions with
707 Lipopolysaccharide and Macrophages/Monocytes. *J Immunol*
708 194(11):5397-5406.
- 709 16. Carter WJ, Cama E, & Huntington JA (2005) Crystal structure of thrombin
710 bound to heparin. *J Biol Chem* 280(4):2745-2749.
- 711 17. Singh S, Kalle M, Papareddy P, Schmidtchen A, & Malmsten M (2013)
712 Lipopolysaccharide interactions of C-terminal peptides from human
713 thrombin. *Biomacromolecules* 14(5):1482-1492.
- 714 18. Petrlova J, *et al.* (2014) Conformational and aggregation properties of the
715 1-93 fragment of apolipoprotein A-I. *Protein Sci* 23(11):1559-1571.
- 716 19. Biancalana M & Koide S (2010) Molecular mechanism of Thioflavin-T
717 binding to amyloid fibrils. *Biochim Biophys Acta* 1804(7):1405-1412.
- 718 20. Fenton JW, Landis BH, Walz DA, & Finlayson JS (1977) *Human thrombin*
719 (Ann Arbor, Ann Arbor Science Publishers).

- 720 21. Liu CY, Nossel HL, & Kaplan KL (1979) The binding of thrombin by fibrin.
721 *J Biol Chem* 254(20):10421-10425.
- 722 22. Lundqvist K, Herwald H, Sonesson A, & Schmidtchen A (2004) Heparin
723 binding protein is increased in chronic leg ulcer fluid and released from
724 granulocytes by secreted products of *Pseudomonas aeruginosa*. *Thromb*
725 *Haemost* 92(2):281-287.
- 726 23. Schmidtchen A (2000) Degradation of antiproteinases, complement and
727 fibronectin in chronic leg ulcers. *Acta Derm Venereol* 80(3):179-184.
- 728 24. Philimonenko AA, Janacek J, & Hozak P (2000) Statistical evaluation of
729 colocalization patterns in immunogold labeling experiments. *J Struct Biol*
730 132(3):201-210.
- 731 25. Landreh M, Johansson J, & Jornvall H (2014) Separate molecular
732 determinants in amyloidogenic and antimicrobial peptides. *J Mol Biol*
733 426(11):2159-2166.
- 734 26. Scott MG, Davidson DJ, Gold MR, Bowdish D, & Hancock REW (2002) The
735 human antimicrobial peptide LL-37 is a multifunctional modulator of
736 innate immune responses. *Journal of Immunology* 169(7):3883-3891.
- 737 27. Soscia SJ, *et al.* (2010) The Alzheimer's disease-associated amyloid beta-
738 protein is an antimicrobial peptide. *PLoS One* 5(3):e9505.
- 739 28. Spitzer P, *et al.* (2016) Amyloidogenic amyloid-beta-peptide variants
740 induce microbial agglutination and exert antimicrobial activity. *Sci Rep*
741 6:32228.
- 742 29. Papareddy P, Morgelin M, Walse B, Schmidtchen A, & Malmsten M (2012)
743 Antimicrobial activity of peptides derived from human ss-amyloid
744 precursor protein. *J Pept Sci* 18(3):183-191.
- 745 30. Pasupuleti M, *et al.* (2009) Antimicrobial activity of human prion protein
746 is mediated by its N-terminal region. *PLoS One* 4(10):e7358.
- 747 31. Zenaro E, *et al.* (2015) Neutrophils promote Alzheimer's disease-like
748 pathology and cognitive decline via LFA-1 integrin. *Nat Med* 21(8):880-
749 886.
- 750 32. Deng X, *et al.* (2014) Lipolysaccharide-Induced Neuroinflammation Is
751 Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and
752 Dendritic Degeneration in Rats. *Adv Alzheimer Dis* 3(2):78-93.
- 753 33. Grammas P & Martinez JM (2014) Targeting thrombin: an inflammatory
754 neurotoxin in Alzheimer's disease. *J Alzheimers Dis* 42 Suppl 4:S537-544.
- 755 34. Petrlova J, *et al.* (2011) A differential association of Apolipoprotein E
756 isoforms with the amyloid-beta oligomer in solution. *Proteins* 79(2):402-
757 416.
- 758 35. Azzam RMA & Bashara NM (1977) *Ellipsometry and polarized light*
759 (North-Holland Pub. Co. ;sole distributors for the U.S.A. and Canada,
760 Elsevier North-Holland, Amsterdam ; New York New York) pp xvii, 529 p.
- 761 36. Malmsten M (1994) Ellipsometry Studies of Protein Layers Adsorbed at
762 Hydrophobic Surfaces. *J Colloid Interf Sci* 166(2):333-342.
- 763 37. Malmsten M, Burns N, & Veide A (1998) Electrostatic and hydrophobic
764 effects of oligopeptide insertions on protein adsorption. *J Colloid Interf Sci*
765 204(1):104-111.
- 766 38. Rydel TJ, *et al.* (1994) Crystallographic structure of human gamma-
767 thrombin. *J Biol Chem* 269(35):22000-22006.

- 768 39. Maier JA, *et al.* (2015) ff14SB: Improving the Accuracy of Protein Side
769 Chain and Backbone Parameters from ff99SB. *J Chem Theory Comput*
770 11(8):3696-3713.
771 40. Monticelli L, *et al.* (2008) The MARTINI coarse-grained force field:
772 Extension to proteins. *Journal of Chemical Theory and Computation*
773 4(5):819-834.
774

775

776 **Author Contributions:** J.P. and A.S. conceived the project and designed the
777 experiments. J.P. performed the experiments, including the peptide production,
778 sample preparation, anti-microbial assays, and fluorescence microscopy. J.P. and F.H.
779 performed the confocal microscopy and immunoblotting. J.P. and M.vd.P. carried out
780 the hemolysis assay; J.P. and M.Mö performed the TEM. P.B. and R.H. contributed
781 the *in silico* modeling data, and M.Ma performed the ellipsometry experiments. J.P.
782 and A.S. wrote the manuscript. All of the authors discussed the results and
783 commented on the final manuscript.

784

785 **Author Information:** Dr. Schmidtchen is a founder of in2cure AB, a company
786 developing therapies based on thrombin-derived host defense peptides. The peptide
787 GKY25 and variants are patent protected. The other authors declare no competing
788 financial interests. Readers are welcome to comment on the online version of the
789 paper. Correspondence and requests for materials should be addressed to J.P.
790 (jitka.petrlova@med.lu.se).

791

792

793

794 **Figure Legends**

795

796 **Figure 1. Analysis of TCP-LPS interactions and LPS-mediated aggregation.** (A)
797 Ellipsometry analysis revealed adsorption of 1 μM of rTCP₉₆, GKY25, and IVE25 at
798 LPS-coated surfaces from 10 mM Tris, pH 7.4 (transformation to mg peptide bound
799 per mg LPS was achieved by dividing by the amount of LPS pre-adsorbed: 1.48 ± 0.38
800 mg/m^2). (B) We used an MST assay to quantify the interaction of rTCP₉₆ with LPS.
801 The peptide IVE25 was used as negative control. The mean values of four
802 measurements \pm their standard deviations are shown. (C) Changes in the secondary
803 structure of rTCP₉₆ triggered by LPS binding were analyzed by CD spectroscopy. The
804 data showed an increase in the β -sheet structure in rTCP₉₆ (10 μM) and an increase in
805 the α -helical content in GKY25 (10 μM) after 30 min of incubation with LPS (100
806 $\mu\text{g}/\text{ml}$) at 37°C. (D) ThT assay, identifying a significant increase in amyloid
807 formation in rTCP₉₆ (at 10 μM) after the addition of 100 $\mu\text{g}/\text{ml}$ of LPS (n=3). (E)
808 Negative-stain transmission electron microscopy revealed the formation of aggregates
809 after incubation of rTCP₉₆ with LPS in 10 mM of Tris, pH 7.4 and supplemented with
810 citrated plasma (CP). The insets show the same samples without LPS treatment using
811 the same magnification. (F and G), Structural changes in digested α -thrombin (α -T, 10
812 μM) by HNE and γ -thrombin (γ -T) were recorded via (F) ThT assay and (G) CD
813 spectroscopy. Thrombin was used as a control. (H and I), TEM analysis of aggregates
814 (1–2 μm in length) present in digested α -thrombin and γ -thrombin (γ -T, 0.1–0.5 μm in
815 length) after incubation with LPS. Only small amounts of aggregates, or none at all,
816 were detected in α -thrombin (α -T) alone, or after addition of LPS, respectively.

817

818 **Figure 2. *In silico* studies.** (A) Structure of the 96aa TCP after 100 ns of atomic-
819 resolution molecular dynamics simulations. The hydrophobic residues are shown in
820 gray. The formation of a new hydrophobic cluster (yellow, labeled residues) of the

821 free TCP between the helix segment 80–96 (red) and the sheet residues 46–60
822 (brown) rely on a twist within the sheet. The extended tail residues formed by
823 residues 46–60 and 80–96 preferentially interact with the lipid tails; the flat patch
824 comprised of residues 1–20 (blue) of the 96aa TCP preferentially interacts with the
825 polar head of LPS. (B) Snapshot from a TCP aggregation simulation showing a
826 representative aggregated state that is mediated by LPS molecules (purple, thick). The
827 TCP backbones are shown in various colors (thin lines). It is apparent that LPS
828 intercalates within the TCP clusters and predominantly connects the preferential
829 interaction sites. (C) Aggregation studies of TCP in the presence (+LPS) and absence
830 (-LPS) of LPS. The panels indicate intermolecular distances of all 8 TCP molecules in
831 the simulation box. Bright areas indicate contact with larger bright segments
832 signifying larger contact areas between molecules. Dark areas indicate that the
833 respective molecules do not interact. Increased aggregation is apparent through the
834 appearance of additional bright areas in the system containing LPS.

835

836 **Figure 3. Co-aggregation of *E. coli* and TCPs.** (A) Confocal microscopy and ThT
837 staining were used to detect *E. coli*-induced amyloid formation of rTCP₉₆ (10 μM) in
838 10 mM Tris buffer, pH 7.4. (B) TEM with negative stain analysis reveals the
839 aggregation of rTCP₉₆-treated bacteria. (C) Fluorescence microscopy shows the
840 agglutination of permeabilized rTCP₉₆-treated bacteria after the addition of FITC dye.
841 The inset shows GKY25-treated *E. coli*. (D) A significant increase in the number of
842 bacteria per aggregates was detected after treatment with 10 μM of rTCP₉₆ compared
843 with GKY25 (n=3). (E) Phagocytosis assay using the macrophage cell line RAW
844 264.7 revealed a significant increase in the phagocytosis of *E. coli* particles pre-
845 treated with rTCP₉₆ (0.5 μM; n=4). (F) Confocal microscopy analysis of phagocytized

846 *E. coli* particles (green) pre-treated with rTCP₉₆ (Alexa 568, red); we used RAW
847 264.7 cells (DAPI, blue).

848

849 **Figure 4. C-terminal fragments of thrombin are found in human acute wound**
850 **fluids, fibrin sloughs, and wound dressings.** (A) Western blotting yielded 11-kDa
851 TCPs in all wound fluid (WF) samples (arrow): 1) rTCP₉₆ (10 μM, 1 μl), 2) rTCP₉₆ in
852 plasma (10 μM, 1 μl), 3–7) WF from patients no. 1–5 (adjusted to same amount of
853 proteins). (B) *Ex vivo*, aggregates were detected by TEM and demonstrated
854 aggregated endogenous TCPs peptides by using gold labeled anti-VFR17 epitope IgG
855 (blue dots) in WF after incubation with LPS (left; 100 μg/ml) or without (right), the
856 insets display a 50x lower magnified overview of the same samples. (C) Formation of
857 aggregates in WF triggered by *E. coli* bacteria. The inset shows WF only, using the
858 same magnification. (D and E) Confocal microscopy, using primary antibodies
859 against TCPs followed by Alexa 568 labeled secondary antibodies and ThT staining,
860 were used to determine amyloid aggregates containing TCPs in the WF in the
861 presence of LPS (D) or *E. coli* (E). (F) Western blotting of extracts from fibrin slough
862 (FS) and wound dressing revealed the presence of 11-kDa TCP fragments in both
863 samples (arrow): 1) rTCP₉₆, 2) rTCP₉₆ in citrate plasma, 3) extract of FS, and 4)
864 extract of wound dressing. (G) Colocalization of endogenous TCPs and LPS in the FS
865 from two patients was detected via TEM analysis. The TCPs were recognized by anti-
866 rabbit IgG with labeled gold particles 10 nm in diameter (blue dots). We detected LPS
867 using IgG against LPS with labeled gold particles 5 nm in diameter (red dots).
868 Colocalization exceeding 90% was observed in both samples. The insets show the
869 same samples using a 4-fold higher magnification.

870

871 **Figure 5. The multiple effects of thrombin and its fragments.** Injury and infection
872 activate the coagulation cascade resulting in Factor X (FX)-mediated cleavage of
873 prothrombin. Thrombin is further cleaved by human neutrophil elastase (HNE),
874 generating TCPs, or autoproteolysed (Trb) (38). Further proteolysis by endogenous
875 HNE, or bacterial elastases such as lasB from *Pseudomonas aeruginosa* (PAE) gives
876 rise to short TCPs. The red colored frame indicates the new findings presented in this
877 work.

878

879 **Supporting Information**

880

881 **Figure S1. Characteristics of rTCP₉₆.** (A) Western blot analysis illustrating α -
882 thrombin (α -T, 10 μ M), α -thrombin digested for 3 h by HNE (α -T+HNE, 0.8 μ g/ml),
883 GKY25 (10 μ M), and rTCP₉₆ (10 μ M). The arrow indicates 11-kDa TCPs. This
884 fragment has been previously characterized and is shown here for comparison and
885 clarity (10). (B) The production and purity of recombinant thrombin C-terminal
886 peptide (rTCP₉₆) was analyzed via SDS-PAGE and Western blotting. (C) Comparison
887 of heparin binding of rTCP₉₆ and γ -thrombin using heparin-affinity fast protein liquid
888 chromatography. Gel-based overlay assay and RDA (D - F) revealed inhibition zones
889 using 10 μ M of both GKY25 and rTCP₉₆ in *E. coli* and GKY25 in *E. coli* and *P.*
890 *aeruginosa* (n=3). (G-H) A viable count assay demonstrated the antimicrobial activity
891 of 3 μ M rTCP₉₆, 3 μ M of GKY25 (a positive control) **and a concentration dependent**
892 **manner from 0.1 to 3 μ M rTCP₉₆** (n=4). (I) rTCP₉₆ (up to 10 μ M) did not demonstrate
893 any hemolytic effects. (J) Kinetic analyses of rTCP₉₆, GKY25, and IVE25 binding to
894 surface-localized LPS are presented. (K) A slot-blot assay demonstrated binding of

895 rTCP₉₆ (2 and 5 µg) to biotin-labeled LPS. The binding was blocked after the addition
896 of heparin.

897

898 **Figure S2. Analyses of aggregation and colocalisation of TCPs.** (A) Effects of
899 GKY25 at the indicated doses on LPS-induced rTCP₉₆ aggregation (100 µg/ml of
900 LPS). The dotted line indicates the fluorescence of pure rTCP₉₆ (10 µM, n=4). (B)
901 Dose dependence of rTCP₉₆ aggregation, which was triggered by 100 µg/ml of LPS, is
902 demonstrated in presence of 10 mM Tris, pH 7.4 (n=4, left panel), or 10 mM Tris, pH
903 7.4 supplemented with 1% citrated human plasma (n=4, right panel). (C) Dynamic
904 light scattering (DLS) measurements were performed to determine the hydrodynamic
905 radii of 1 µM of rTCP₉₆, 10 µg/ml of LPS, and LPS-treated rTCP₉₆ (n=5). GKY25
906 was used as a negative control. (D) The far-UV CD spectra of rTCP₉₆ (10 µM) in the
907 presence and absence of LPS (100 µg/ml) in Tris buffer was recorded after incubation
908 for 10 and 120 min. ThT assay (E) and DLS analyses (F) were performed of rTCP₉₆
909 (10 µM) with or without LPS (100 µg/ml) addition after the indicated incubation
910 times (n=4). (G) [The representative image of Western blot shows 1-4\) the calibration](#)
911 [curve \(0.1, 0.5, 1 and 2 µM of rTCP₉₆\) and 5-6\) the wound fluids of the same volumes](#)
912 [as the standards \(n=4\).](#) (H) Analysis of clustering and colocalization patterns of TCPs
913 and LPS. The histogram depicts PCCF function values for intervals of distances. One
914 microscopic image from each sample was analyzed. A PCCF value above 1
915 corresponds to non-random mutual distribution-colocalization of two types of
916 particles (24).

917

918 **Figure S3. Computational prediction of co-aggregation of TCP and LPS.**

919 Interactions of eight 96aa TCP molecules and LPS from five random starting

920 orientations were predicted.

921

922 **Figure S4. Control microscopy analysis.** Control confocal microscopy analysis of
923 phagocytized *E. coli* particles (green) and rTCP₉₆ (Alexa 568, red) incubated with
924 RAW 264.7 cells (DAPI, blue).

925

926 **Movie S1. TCP aggregation simulations in the presence of LPS.** Simulations (1
927 μ s) of eight 96aa TCP molecules incubated with LPS in a cubic box in one random
928 starting orientation. The movie visualizes the observed trajectories in sequence.
929 Lipopolysaccharide intercalates in the spaces between the TCP molecules (purple,
930 thick), thereby bridging the gap between individual TCPs (backbones shown in
931 various colors, thin lines).

932 **Table S1**

933 **Secondary structure of TCP.** Secondary structure of the TCP region (amino acids
934 527-622, prothrombin labeling) was deduced from the crystal structure of α - and γ -
935 thrombin, computed from the CD spectra of rTCP₉₆, using k2D3 ([http://cbdm-](http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d3/)
936 [01.zdv.uni-mainz.de/~andrade/k2d3/](http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d3/)), or derived from *in silico* modeling data (see
937 Methods).